Literature analysis of treatment outcome of Multi-drug resistant tuberculosis with different regimens

Abstract

Abstract:  Methods All the MDR treatment-related articles in “Medline” database published from 1996 to 2010 were searched. s of these papers were screened to find the full text of relevant articles. Final selection of articles was determined by inclusion and exclusion criteria.  Results A total of 1286 related English abstracts were searched originally, 28 articles were enrolled based on inclusion and exclusion criteria eventually. Among which 2 articles adopted standard treatment regimen, 1 with empirical regimen, 2 with National TB Program (NTP) standard short-course treatment regimen, and 23 with individualized regimen based on drug susceptibility test. Treatment success rate with individualized regimen is 61.2%, significantly higher than standardized MDR regimen of 52% and NTP standard short-course treatment of 39.2% (P<0.05). There is no statistical difference in treatment success rate between individualized regimen and empirical-based regimen (P>0.05). Conclusion Individualized treatment regimen should be adopted in regions where conditions permit; NTP recommended standard short course treatment is not enough for MDR-TB treatment.

Key words: tuberculosis, multi drug-resistant/drug therapy, clinical protocols, treatment outcome

CLC Number:

Du Jian,Xu Caihong,Li Qi,Jiang Xiaoying,Ma Yan,Gao Jingtao,Duanmu Hongjin,Fu Yu,Li Liang. Literature analysis of treatment outcome of Multi-drug resistant tuberculosis with different regimens[J]. Chinese Journal of Antituberculosis, 2010, 32(8): 7-12.

References

［1］WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis［M］. Geneva: World Health Organization,2006：21.
［2］ WHO. Global Tuberculosis Control 2009: Epidemiology, Strategy and Financing［R］. 2009：49.
［3］中华人民共和国卫生部. 2000年全国结核病流行病学抽样调查资料汇编［M］.北京：人民卫生出版社, 2003：42.
［4］ Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment Outcome of Multidrug-Resistant Tuberculosis among Vietnamese Immigrants［J］. Int J Tuberc Lung Dis, 2005, 9(2):164-169.
［5］ Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of Multiple Drug-Resistant Tuberculosis(MDR-TB) in Iran［J］. Int J Infect Dis, 2005, 9(6):317-322.
［6］ Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of Multidrug-Resistant Tuberculosis in San Francisco: an Outpatient-Based Approach［J］. Clin Infect Dis, 2005, 40(7):968-975.
［7］ Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and Outcome Analysis of 205 Patients with Multidrug-Resistant Tuberculosis［J］. Am J Respir Crit Care Med, 2004,169(10):1103-9.
［8］ Palmero DJ, Ambroggi M, Brea A, De Lucas M, Fulgenzi A, Martínez D, Mosca C, Musella R, Natiello M, Gonzalez C, Abbate E. Treatment and Follow-up of HIV-Negative Multidrug-Resistant Tuberculosis Patients in an Infectious Diseases Reference Hospital, Buenos Aires, Argentina［J］. Int J Tuberc Lung Dis, 2004, 8(6):778-784.
［9］ Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V. Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment Outcome［J］. Ann Intern Med, 2006, 144(9):650-659.
［10］Tahao lu K, Trün T, Sevim T, Ata G, Kir A, Karasulu L, Ozmen I, Kapakli N. The Treatment of Multidrug-Resistant Tuberculosis in Turkey［J］. N Engl J Med. 2001, 345(3):170-174.
［11］ Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, Standardized Regimens for Multidrug-Resistant Tuberculosis in South Korea［J］. Int J Tuberc Lung Dis, 2004, 8(3):361-368.
［12］ Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a Standardised Regimen for Multidrug-Resistant Tuberculosis in Bangladesh［J］. Int J Tuberc Lung Dis, 2004, 8(5):560-567.
［13］ Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens［J］. Chest, 2000, 117(3):744-751.
［14］ Ollé-Goig JE, Sandy R. Outcomes of Individualised Treatment for Multidrug-Resistant Tuberculosis before DOTS-plus［J］. Int J Tuberc Lung Dis, 2005 Jul;9(7):765-770.
［15］ Senaratne WV. Outcome of Treatment of Multidrug Resistant Tuberculosis［J］. Ceylon Med J. 2004, 49(3):86-87.
［16］ International Organization for Migration (IOM) Tuberculosis Working Group. Outcome of Second-Line Tuberculosis Treatment in Migrants from Vietnam［J］. Trop Med Int Health, 1998, 3(12):975-980.
［17］ Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP. Outcome of Pulmonary Multidrug-Resistant Tuberculosis: a 6-yr Follow-up Study［J］. Eur Respir J, 2006, 28(5):980-985.
［18］ Park SK, Kim CT, Song SD. Outcome of Chemotherapy in 107 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin［J］. Int J Tuberc Lung Dis, 1998, 2(11):877-884.
［19］ Reechaipichitkul W. Multidrug-Resistant Turculosis at Srinagarind Hospital, Khon Kaen, Thailand［J］. Southeast Asian J Trop Med Public Health, 2002, 33(3):570-574.
［20］ Escudero E, Pea JM, Alvarez-Sala R, Vázquez JJ, Ortega A. Multidrug-Resistant Tuberculosis without HIV Infection: Success with Individualised Therapy［J］. Int J Tuberc Lung Dis, 2006, 10(4):409-414.
［21］ Tupasi TE, Quelapio MI, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, Belen VT, Arnisto NM, Rivera AB, Grimaldo ER, Derilo JO, Dimarucut W, Arabit M, Urboda D. DOTS-Plus for Multidrug-Resistant Tuberculosis in the Philippines: Global Assistance Urgently Needed［J］. Tuberculosis (Edinb), 2003, 83(1-3):52-58.
［22］ Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rüsch-Gerdes S, Varaine F. Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries［J］. Int J Tuberc Lung Dis, 2005 , 9(10):1147-1154.
［23］ Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru［J］. N Engl J Med, 2003, 348(2):119-128.
［24］ Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory Treatment of Multidrug-Resistant Pulmonary Tuberculosis Patients at a Chest Clinic［J］. Int J Tuberc Lung Dis, 2001, 5(12):1129-1136.
［25］ Trün T, Güngr G, Ozmen I, Blükba?瘙塂i Y, Maden E, Biaki B, Ata G, Sevim T, Tahao lu K. Side Effects Associated with the Treatment of Multidrug-Resistant Tuberculosis［J］. Int J Tuberc Lung Dis, 2005 , 9(12):1373-1377.
［26］ Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC. Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in 6 Countries［J］. JAMA, 2000, 283(19):2537-2545.
［27］ Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of Multidrug-resistant Tuberculosis in Italy［J］. Int J Tuberc Lung Dis, 2005, 9(5):507-513.
［28］ Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ. Treatment Outcomes for HIV-Uninfected Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis［J］. Clin Infect Dis, 2008, 47(4):496-502.
［29］ Heller T, Lessells RJ, Wallrauch CG, Brnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa［J］. Int J Tuberc Lung Dis, 2010, 14(4):420-426.
［30］ Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of Extensive Drug Resistance on Treatment Outcomes in Non–HIV-Infected Patients with Multidrug-Resistant Tuberculosis［J］. Clin Infect Dis, 2007, 45(10):1290-1295.
［31］ Karagz T, Yazicio lu Moin O, Pazarli P, Senol T, Yeti?瘙塂 Duman D, Duman G, Saltürk C, Unal O, Halezero lu S. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment Outcome［J］. Tuberk Toraks, 2009, 57(4):383-392.

[1]	LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008.
[2]	Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893.
[3]	JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902.
[4]	ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909.
[5]	ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915.
[6]	LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920.
[7]	MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925.
[8]	WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930.
[9]	LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936.
[10]	LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941.
[11]	SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947.
[12]	DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955.
[13]	DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961.
[14]	MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972.
[15]	NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980.